iGenix Announces CLIA Approval of Diagnostic Assay on BeadXpress
iGenix today announced it has received CLIA approval for its first diagnostic assay created to run on the Illumina BeadXpress.
Seattle, WA (PRWEB) July 26, 2011
iGenix today announced it has received CLIA approval for its first diagnostic assay created to run on the Illumina BeadXpress, a high-throughput genomic analysis platform manufactured by Illumina Inc. The pharmacogenomics assay certified was built as a “proof-of-principle” test for CLIA certification, and is one of several in the iGenix R&D pipeline.
“We are expanding our services to better assist researchers in understanding the genetic variability associated with drug response and predisposition.”, said Tera Eerkes, iGenix’s CSO and founder. She added, “Obtaining CLIA certification provides independent verification of our firm’s expertise in using high-throughput molecular analysis platforms with clinical samples for both research and diagnostic purposes. We see huge potential to aid drug developers in accelerating their research process and bringing products to market.”
The iGenix laboratory is purpose-built to support genomics-based drug development with services including DNA purification from clinical samples, targeted genotyping for clinical study participation or qualification, and custom/companion diagnostic assay development.
About iGenix, Inc.
Founded by Tera Eerkes Ph.D. and Dr. Carl Newman, M.D, in 2007, iGenix provides contract research and laboratory services to researchers and physicians seeking to understand the complex nature of disease. iGenix has particular expertise in biomarker evaluation, specifically helping clients develop new diagnostic assays suitable for the BeadXpress platform.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/7/prweb8669306.htm